- Home
- ICCH vs OVID Comparison
ICCH vs OVID Comparison
Compare ICCH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCH
- OVID
- Stock Information
- Founded
- ICCH 1950
- OVID 2014
- Country
- ICCH United States
- OVID United States
- Employees
- ICCH N/A
- OVID N/A
- Industry
- ICCH Property-Casualty Insurers
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- ICCH Finance
- OVID Health Care
- Exchange
- ICCH Nasdaq
- OVID Nasdaq
- Market Cap
- ICCH 68.8M
- OVID 73.1M
- IPO Year
- ICCH 2017
- OVID 2017
- Fundamental
- Price
- ICCH $23.86
- OVID $1.00
- Analyst Decision
- ICCH
- OVID Strong Buy
- Analyst Count
- ICCH 0
- OVID 5
- Target Price
- ICCH N/A
- OVID $4.04
- AVG Volume (30 Days)
- ICCH 7.8K
- OVID 296.7K
- Earning Date
- ICCH 11-04-2024
- OVID 11-12-2024
- Dividend Yield
- ICCH N/A
- OVID N/A
- EPS Growth
- ICCH 42.86
- OVID N/A
- EPS
- ICCH 2.16
- OVID N/A
- Revenue
- ICCH $92,541,259.00
- OVID $631,695.00
- Revenue This Year
- ICCH N/A
- OVID $71.38
- Revenue Next Year
- ICCH N/A
- OVID $5,144.81
- P/E Ratio
- ICCH $11.05
- OVID N/A
- Revenue Growth
- ICCH 14.09
- OVID 113.21
- 52 Week Low
- ICCH $14.78
- OVID $0.68
- 52 Week High
- ICCH $23.95
- OVID $4.10
- Technical
- Relative Strength Index (RSI)
- ICCH 74.33
- OVID 39.12
- Support Level
- ICCH $23.23
- OVID $0.99
- Resistance Level
- ICCH $23.35
- OVID $1.09
- Average True Range (ATR)
- ICCH 0.10
- OVID 0.08
- MACD
- ICCH 0.04
- OVID -0.01
- Stochastic Oscillator
- ICCH 89.77
- OVID 2.26
About ICCH ICC Holdings Inc.
ICC Holdings Inc is a specialty insurance carrier underwriting commercial multi-peril, liquor liability, worker's compensation, and umbrella liability coverages for the food and beverage industry. The company markets its products through a network of independent agents in Colorado, Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri, Pennsylvania, Ohio, and Wisconsin.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.